2. About Brisardik
Established in 1987
Based in Columbus, Ohio
More than 500 physicians,
chemists, and lab assistants
Known for popular ADHD medications
and anti depressants
Creator of Intelliboost
3. Intelliboost
Taken once daily
Prescription
Gradually builds up
Strengthen and develops decision
making and processing functions
Could be sold in a variety of sizes
Study to determine if medication
works and is ready for sale
4. Study Participants
Randomly selected 60 adults
Customers and research volunteers
Intelligence testing
30 given Intelliboost, 30 placebos
Intelligence retesting
5. Data Collection
Participant IDs
Test scores recorded
Data sorted in several ways including:
All participants
Intelliboost recipients
Placebo recipients
Gender
Age
Improvements made
8. Data by Age
58 and
18-27 28-37 38-47 48-57 older
Intelliboost 6 9 8 5 2
Placebo 5 8 9 6 2
Increased IQ with Intelliboost Increased IQ with Placebo
January March January March
18-27 3 1 18-27 2 1
28-37 4 2 28-37 4 2
38-47 5 3 38-47 4 2
48-57 4 1 48-57 2 1
58 & Older 1 0 58 & Older 0 0
9. Summary Output
All Data
The independent variable medicine/placebo
The dependent variable the IQ score
Scatter diagram
All Participants Before/After
160
140
120
100
After
80
60
40
20
0
0 20 40 60 80 100 120 140 160
Before
10. Linear Correlation
All Data
Coefficient of correlation-r=0.9911 r = 0.991146
p = 0.000000
Strong positive correlation
y=a+bx
Represents a good model a=7.663276883
b=.9473999051
The line fits the points well n=60
7.663276883+.94739990
r suggests there is a linear correlation 51(60)=64.5073
between IQ scores and the use of a
placebo or new medication slope = 1.03691245
11. All Data Continued…
A few outliers based on the scatter diagram are (94,105),
(96,106), (97,103), (75,75), and (129, 135)
Using (129,135) and entering it into the regression line the
solution would be: 7.6633+.9474(129)=130
This predicted answer is close to the observed answer of 135.
This is not too far beyond the scope of available data.
The point with the largest residual is (94,105).
7.6633+.9474(94)=97
105-97=8 equaling the largest residual.
This point does not accurately represent the regression line.
12. Summary Output-Intelliboost
The independent variable the medicine
The dependent variable the IQ score
Scatter diagram
Patients Taking Intelliboost
160
140
120
100
After
80 Series1
60 Linear (Series1)
40
20
0
0 50 100 150 200
Before
13. Correlation - Intelliboost
Coefficient of correlation r=.9847 slope=1.02528284
5
Strong positive correlation p=0.0000
r=0.9847
This represents a good model r square=0.9696
y=a+bx
The line fits the points well a=9.4258
b=0.9457
r suggests there is a linear correlation between n=30
IQ scores and the use of the new medication 9.4258+.9457x
14. Intelliboost Continued…
A few outliers based on the scatter diagram are (113,125) and (99,110).
Using point (140,143) and entering it into the regression line:
y=9.4258+0.9457(140)=142 with a residual of 1.
The predicted answer is close to the observed answer of 143. This is not
too far beyond the scope of available data.
97% of participants saw a change in their IQ after taking the new medicine
y=9.4258+.9457(99)=103 with a residual difference of 7.
y=9.4258+.9457(113)=116 with a residual difference of 9.
This point has the largest residual value and does not accurately
represent the regression line.
15. Summary Output-Placebo
The independent variable the placebo
The dependent variable the IQ score
Scatter diagram
Patients Taking New Placebo
160
140
120
100
After
80 Series1
60 Linear (Series1)
40
20
0
0 50 100 150 200
Before
16. Correlation - Placebo
Coefficient of correlation r=0.9963
slope=1.04585667
Strong positive correlation p=0.0000
r=0.9963
This represents a good model r square=0.9926
y=a+bx
The line fits the points well a=5.8513
b=0.9491
r suggests there is a linear correlation between n=30
the IQ scores and the use of the placebo 5.8513+0.9491
17. Placebo Continued…
There are no outliers on the placebo scatter diagram
Using point (80,82) and entering it into the regression line:
y=5.8513+0.9491(80)=82
It has a residual of 0.
The predicted answer is exactly the same as the observed answer of
82. This is exactly within the scope of available data.
Using the point (97,103) and entering it into the regression line:
y=5.8513+.9491(97)=98 with a residual of 5.
This point has the largest residual value and does not accurately
represent the regression line.
18. ANOVA
Intelliboost
Test criteria ANOVA
f= .33425
p=.5654
Test results
Placebo
Importance of the mean ANOVA
f=.00809
p=.9286
19. Paired Test
Breakdown of test Intelliboost Placebo
Paired Test Paired Test
t= 4.55279 t= 1.2867
Analyzing results p=.00004387 p= .10418
x= 3.4 x= -.5333
Sx=4.09035 Sx= 2.2702
Validity of test n=30 n= 30
Critical value for 29 deg of freedom is : 2.045
20. Final Recommendations
Move forward with Intelliboost.
Seek final approval from the United States
Food and Drug Administration
Begin marketing Intelliboost
Begin production and pharmaceutical
distribution of Intelliboost
22. Footnote
Note: Brisardik Pharmaceuticals and Intelliboost
were invented for the sake of this project. All data
was created for the project purposes only. Data
collection methods are designed to show how the
data would have been collected if the company,
drug and study were real.
